BioVinc Secures Multi-Million Dollar SBIR Fast-Track Grant from NIH/NIAID to Advance Treatment for Infected Fractures
BioVinc is thrilled to announce it has been awarded a prestigious multi-million dollar SBIR Fast-Track Phase I/II grant from the National Institutes of Health (NIH/NIAID). This funding will accelerate our research and development of cutting-edge treatments targeting infected fractures, a critical unmet medical need. Patients suffering from open fractures face an alarmingly high risk of […]
BioVinc Awarded SBIR Phase II Grant by NIH/NIAID to Advance Novel Treatment for Prosthetic Joint Infections
BioVinc is proud to announce that it has received a multi-million prestigious SBIR Phase II grant from the National Institutes of Health (NIH/NIAID). This grant will accelerate our efforts in the research and development of new treatments targeting the significant unmet medical need of prosthetic joint infections. Deep bone infections, such as prosthetic joint infections, […]
BioVinc Receives an STTR Phase II Grant from the National Institutes of Health
BioVinc is pleased to announce that its research team has been awarded an STTR Phase II grant from the National Institutes of Health (NIH/NIDCR). This grant will support a highly promising collaboration with Dr. Parish P. Sedghizadeh at the University of Southern California Dental School (USC) (https://dentists.usc.edu/dentists/parish-sedghizadeh/). In this effort, BioVinc will continue to pursue […]
BioVinc Receives an SBIR Phase II Grant from the National Institutes of Health
BioVinc is pleased to announce that it has been awarded an SBIR Phase II grant from the National Institutes of Health (NIH/NIDCR). This grant will facilitate research and development towards the prevention/treatment of the very devastating dental affliction: osteonecrosis of the jaw (ONJ). ONJ has been reported as a rare but severe complication of oral […]